Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai, Aibing Xu, Shundong Cang, Chengyou Du, Qiu Li, Yinying Lu, Yajin Chen, Yabing Guo, Zhendong Chen, Baorui Liu, Weidong Jia, Jian Wu, Junye Wang, Guoliang Shao, Bixiang Zhang, Yunfeng Shan, Zhiqiang Meng, Jianbing Wu, Shanzhi Gu, Wei Yang, Chao Liu, Xuetao Shi, Zhenyuan Gao, Tao Yin, Jiuwei Cui, Ming Huang, Bao-Cai Xing, Yilei Mao, Gao‐Jun Teng, Yanru Qin, Jinhai Wang, Feng Xia, Guowen Yin, Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan